These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 29552922)

  • 21. [Hepatitis C virus infection--after 12 years. Advances in the management of chronic hepatitis C].
    Pár A
    Orv Hetil; 2002 Dec; 143(48):2667-74. PubMed ID: 12501575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Milestones in the discovery of hepatitis C.
    Campollo O; Amaya G; McCormick PA
    World J Gastroenterol; 2022 Oct; 28(37):5395-5402. PubMed ID: 36312838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
    Hunyady B; Kovács B; Battyáni Z
    Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Anti-hepatitis C virus strategy targeting host entry factor claudin-1].
    Fukasawa M
    Uirusu; 2015; 65(2):245-254. PubMed ID: 27760923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure.
    Colpitts CC; Baumert TF
    Viruses; 2016 Aug; 8(8):. PubMed ID: 27537906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Directly acting antivirals against hepatitis C virus.
    Soriano V; Vispo E; Poveda E; Labarga P; Martin-Carbonero L; Fernandez-Montero JV; Barreiro P
    J Antimicrob Chemother; 2011 Aug; 66(8):1673-86. PubMed ID: 21652618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.
    Kohli A; Kattakuzhy S; Sidharthan S; Nelson A; McLaughlin M; Seamon C; Wilson E; Meissner EG; Sims Z; Silk R; Gross C; Akoth E; Tang L; Price A; Jolley TA; Emmanuel B; Proschan M; Teferi G; Chavez J; Abbott S; Osinusi A; Mo H; Polis MA; Masur H; Kottilil S
    Ann Intern Med; 2015 Dec; 163(12):899-907. PubMed ID: 26595450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of direct antiviral agent failures.
    Buti M; Esteban R
    Clin Mol Hepatol; 2016 Dec; 22(4):432-438. PubMed ID: 28081594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of chronic hepatitis C virus infection after liver transplantation.
    Agarwal K; Barnabas A
    Dig Liver Dis; 2013 Sep; 45 Suppl 5():S349-54. PubMed ID: 24091115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiology of Hepatitis C Virus: A Battle on New Frontiers.
    Shire NJ; Sherman KE
    Gastroenterol Clin North Am; 2015 Dec; 44(4):699-716. PubMed ID: 26600215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development.
    Pawlotsky JM
    Semin Liver Dis; 2014 Feb; 34(1):22-9. PubMed ID: 24782255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals.
    Ahmed A; Felmlee DJ
    Viruses; 2015 Dec; 7(12):6716-29. PubMed ID: 26694454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevir.
    Susser S; Flinders M; Reesink HW; Zeuzem S; Lawyer G; Ghys A; Van Eygen V; Witek J; De Meyer S; Sarrazin C
    Antimicrob Agents Chemother; 2015 May; 59(5):2746-55. PubMed ID: 25712364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular virology of chronic hepatitis B and C: parallels, contrasts and impact on drug development and treatment outcome.
    Delaney WE
    Antiviral Res; 2013 Jul; 99(1):34-48. PubMed ID: 23602852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Present and future therapy for hepatitis C virus.
    Cornberg M; Deterding K; Manns MP
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):781-93. PubMed ID: 17140355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of boceprevir: a first-in-class direct antiviral treatment for chronic hepatitis C infection.
    Hazuda DJ; Burroughs M; Howe AY; Wahl J; Venkatraman S
    Ann N Y Acad Sci; 2013 Jul; 1291():69-76. PubMed ID: 23859802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Rethinking the reimbursement policy of direct acting antivirals against chronic hepatitis C].
    Girardin F; Goossens N; Vernaz N; Negro F
    Rev Med Suisse; 2015 Sep; 11(484):1610-2, 1614-6. PubMed ID: 26502622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies.
    Shahid I; ALMalki WH; Hafeez MH; Hassan S
    Crit Rev Microbiol; 2016 Aug; 42(4):535-47. PubMed ID: 25373616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
    Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
    Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.